3-hydroxykynurenine has been researched along with Schizophrenia in 10 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 7.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Several lines of evidence suggest that up-regulation of immune response and alterations of kynurenine pathway function are involved in pathogenesis of schizophrenia." | 7.85 | Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia. ( Flis, M; Kandefer-Szerszeń, M; Karakuła-Juchnowicz, H; Kocki, T; Rosa, W; Szymona, K; Urbańska, EM; Zdzisińska, B, 2017) |
| "Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems." | 5.36 | Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. ( Dougherty, GG; Kaddurah-Daouk, R; Keshavan, MS; Krishnan, RR; Matson, WR; McEvoy, J; Montrose, DM; Reddy, RD; Rozen, S; Yao, JK, 2010) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 3.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "A subgroup of individuals with mood and psychotic disorders shows evidence of inflammation that leads to activation of the kynurenine pathway and the increased production of neuroactive kynurenine metabolites." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| " In contrast, schizophrenia and psychosis are hypothesized to arise from increased metabolism of the NMDA receptor antagonist, kynurenic acid (KynA), leading to hypofunction of GABAergic interneurons, the disinhibition of pyramidal neurons and striatal hyperdopaminergia." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Several lines of evidence suggest that up-regulation of immune response and alterations of kynurenine pathway function are involved in pathogenesis of schizophrenia." | 3.85 | Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia. ( Flis, M; Kandefer-Szerszeń, M; Karakuła-Juchnowicz, H; Kocki, T; Rosa, W; Szymona, K; Urbańska, EM; Zdzisińska, B, 2017) |
| "The association between the pro-inflammatory state of schizophrenia and increased tryptophan degradation into kynurenine has been reported." | 3.77 | Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. ( Kim, YK; Leonard, BE; Mueller, HH; Myint, AM; Scharpé, S; Schwarz, MJ; Steinbusch, HW; Verkerk, R; Zach, J, 2011) |
| "The data demonstrate an impairment of brain kynurenine pathway metabolism in schizophrenia, resulting in elevated kynurenate levels and suggesting a possible concomitant reduction in glutamate receptor function." | 3.71 | Increased cortical kynurenate content in schizophrenia. ( Medoff, D; Rassoulpour, A; Roberts, RC; Schwarcz, R; Tamminga, CA; Wu, HQ, 2001) |
| " In rats, chronic (6-months) treatment with haloperidol did not cause an increase in kynurenate levels in the frontal cortex, indicating that the elevation observed in schizophrenia is not due to antipsychotic medication." | 3.71 | Increased cortical kynurenate content in schizophrenia. ( Medoff, D; Rassoulpour, A; Roberts, RC; Schwarcz, R; Tamminga, CA; Wu, HQ, 2001) |
| "Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 1.46 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems." | 1.36 | Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. ( Dougherty, GG; Kaddurah-Daouk, R; Keshavan, MS; Krishnan, RR; Matson, WR; McEvoy, J; Montrose, DM; Reddy, RD; Rozen, S; Yao, JK, 2010) |
| "Kynurenine levels were elevated in schizophrenic cases in Brodmann areas 9 (35." | 1.31 | Increased cortical kynurenate content in schizophrenia. ( Medoff, D; Rassoulpour, A; Roberts, RC; Schwarcz, R; Tamminga, CA; Wu, HQ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Beggiato, S | 1 |
| Notarangelo, FM | 1 |
| Sathyasaikumar, KV | 1 |
| Giorgini, F | 1 |
| Schwarcz, R | 2 |
| Curto, M | 1 |
| Lionetto, L | 1 |
| Fazio, F | 1 |
| Corigliano, V | 1 |
| Comparelli, A | 1 |
| Ferracuti, S | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Baldessarini, RJ | 1 |
| Oxenkrug, G | 1 |
| Bernstein, HG | 1 |
| Guest, PC | 1 |
| van der Hart, M | 1 |
| Roeser, J | 1 |
| Summergrad, P | 1 |
| Steiner, J | 1 |
| Johansson, AS | 1 |
| Owe-Larsson, B | 1 |
| Asp, L | 1 |
| Kocki, T | 2 |
| Adler, M | 1 |
| Hetta, J | 1 |
| Gardner, R | 1 |
| Lundkvist, GB | 1 |
| Urbanska, EM | 2 |
| Karlsson, H | 1 |
| Szymona, K | 1 |
| Zdzisińska, B | 1 |
| Karakuła-Juchnowicz, H | 1 |
| Kandefer-Szerszeń, M | 1 |
| Flis, M | 1 |
| Rosa, W | 1 |
| Yao, JK | 2 |
| Dougherty, GG | 2 |
| Reddy, RD | 2 |
| Keshavan, MS | 2 |
| Montrose, DM | 2 |
| Matson, WR | 2 |
| Rozen, S | 1 |
| Krishnan, RR | 1 |
| McEvoy, J | 2 |
| Kaddurah-Daouk, R | 2 |
| Condray, R | 1 |
| Haas, GL | 1 |
| Myint, AM | 1 |
| Schwarz, MJ | 1 |
| Verkerk, R | 1 |
| Mueller, HH | 1 |
| Zach, J | 1 |
| Scharpé, S | 1 |
| Steinbusch, HW | 1 |
| Leonard, BE | 1 |
| Kim, YK | 1 |
| Rassoulpour, A | 1 |
| Wu, HQ | 1 |
| Medoff, D | 1 |
| Tamminga, CA | 1 |
| Roberts, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 3-hydroxykynurenine and Schizophrenia
| Article | Year |
|---|---|
3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chromatography, High Pressu | 2011 |
9 other studies available for 3-hydroxykynurenine and Schizophrenia
| Article | Year |
|---|---|
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo | 2018 |
Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Ky | 2019 |
Plasma xanthurenic acid in a context of insulin resistance and obesity in schizophrenia.
Topics: Case-Control Studies; Humans; Insulin Resistance; Kynurenic Acid; Kynurenine; Obesity; Schizophrenia | 2019 |
Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
Topics: Adult; Bipolar Disorder; Cells, Cultured; Cytokines; Female; Fibroblasts; Gene Expression Regulation | 2013 |
Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Interferon-alpha; Interleukin-4; Kynurenic A | 2017 |
Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Hydroxyindoleacetic Acid; Kynurenine; Male; | 2010 |
Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.
Topics: Adult; Algorithms; Antipsychotic Agents; Chromatography, High Pressure Liquid; Diagnostic and Statis | 2011 |
Increased cortical kynurenate content in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Female; Frontal Lobe; Haloperidol; Hu | 2001 |